Harmony Biosciences Holdings (HRMY) Total Liabilities (2019 - 2026)

Harmony Biosciences Holdings has disclosed Total Liabilities across 8 years of filings, most recently posting $361.5 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $361.5 million, up 7.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $361.5 million (up 7.9% YoY), and the FY2025 annual result was $401.4 million, up 18.05% from the prior year.
• Total Liabilities came in at $361.5 million for Q1 2026 at Harmony Biosciences Holdings, down from $401.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $401.4 million in Q4 2025 to a low of $249.5 million in Q1 2022.
• The 5-year median for Total Liabilities is $331.3 million (2024), against an average of $317.4 million.
• Across the five-year window, Total Liabilities climbed 27.09% in 2023 and retreated 1.28% in 2024, its largest moves.
• Harmony Biosciences Holdings' Total Liabilities stood at $271.0 million in 2022, then gained by 27.09% to $344.5 million in 2023, then declined by 1.28% to $340.0 million in 2024, then climbed by 18.05% to $401.4 million in 2025, then declined by 9.95% to $361.5 million in 2026.
• The last three Total Liabilities figures came in at $361.5 million (Q1 2026), $401.4 million (Q4 2025), and $373.1 million (Q3 2025), per Business Quant data.